DrugPatentWatch Database Preview

FETZIMA Drug Profile

see a sample report or, see our see our flat-rate plans

Which patents cover Fetzima, and when can generic versions of Fetzima launch?

Fetzima is a drug marketed by Allergan Sales Llc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in twenty-seven countries.

The generic ingredient in FETZIMA is levomilnacipran hydrochloride. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levomilnacipran hydrochloride profile page.

Summary for FETZIMA

International Patents:	54
US Patents:	3
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	42
Clinical Trials:	5
Patent Applications:	9
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FETZIMA
DailyMed Link:	FETZIMA at DailyMed

Drug patent expirations by year for FETZIMA

Pharmacology for FETZIMA

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Synonyms for FETZIMA

(+)-(1S,2R)-MILNACIPRAN
(+)-Milnacipran
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
(1S-cis)-Milnacipran Hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
(1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1S,2R)-2-Aminomethyl-1-phenyl-cyclopropanecarboxylic acid diethylamide
(1S,2R)-milnacipran
(1S,2R)-Milnacipran Hydrochloride
101152-94-7
152M947
175131-60-9
371U2ZK31U
96847-54-0
AC1OCEN6
AC1OCEN8
AK481450
AKOS025311514
API0003393
AS-12868
AT-28508
BDBM50032379
C15H22N2O.HCl
CCG-231710
CHEBI:136040
CHEMBL2105732
CHEMBL99946
cis-(+)-Milnacipran Hydrochloride
cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
CS-4972
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (1S,2R)-
D02XOK
D10072
D10133
Dalcipran
DB08918
F 2695
F 2695 hydrochloride
F-2207
F-2695
f2-695
F2695
Fetzima (TN)
GJJFMKBJSRMPLA-DZGCQCFKSA-N
GTPL7435
HY-B0168B
Ixel
J10386
Joncia
K-0218
Levomilnacipran
Levomilnacipran (USAN/INN)
Levomilnacipran [USAN:INN]
Levomilnacipran HCl
LEVOMILNACIPRAN HYDROCHLORIDE
Levomilnacipran hydrochloride (USAN)
Levomilnacipran hydrochloride [USAN]
M2133
MFCD00901293
MFCD18433402
Midalcipran hydrochloride
Milnacipram
Milnacipran ((1S-cis) hydrochloride)
Milnacipran (1S-cis) hydrochloride
Milnacipran HCl
Milnacipran hydrochloride
Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base)
MolPort-019-939-251
Savella
SCHEMBL1148742
SCHEMBL1414867
TN-912
Toledomin
UGM0326TXX
UNII-371U2ZK31U
UNII-G56VK1HF36 component GJJFMKBJSRMPLA-DZGCQCFKSA-N
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N
UNII-UGM0326TXX
ZINC506

US Patents and Regulatory Information for FETZIMA

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Sales Llc	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Allergan Sales Llc	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y	Y		➤ Sign Up
Allergan Sales Llc	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Allergan Sales Llc	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-003	Jul 25, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for FETZIMA

Drugname	Dosage	Strength	RLD	Submissiondate
➤ Subscribe	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	➤ Subscribe	2017-07-25

Non-Orange Book US Patents for FETZIMA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,074,833	Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug	➤ Sign Up
9,259,403	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide	➤ Sign Up
7,005,452	Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

see a sample report or, see our see our flat-rate plans

International Patents for FETZIMA

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration
Japan	2010090143	➤ Sign Up
Japan	5431136	➤ Sign Up
China	1750817	➤ Sign Up
New Zealand	575218	➤ Sign Up
Country	Document Number	Estimated Expiration

Summary for FETZIMA

Pharmacology for FETZIMA

Synonyms for FETZIMA

Paragraph IV (Patent) Challenges for FETZIMA

For more information try a trial or see the plans and pricing